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Abstract 
Signal transducer and activator of transcription 3 (STAT3) controls many biological 
processes including differentiation, survival, proliferation, and angiogenesis. In normal healthy 
cells, STAT3 is tightly regulated to maintain a momentary active state. However, aberrant or 
constitutively activated STAT3 has been observed in many different cancers and constitutively 
activated STAT3 has been shown to associate with poor prognosis and tumor progression. For this 
reason, STAT3 has been studied as a possible target in the treatment of many different types of 
cancers. However, despite decades of research, a FDA-approved STAT3 inhibitor has yet to 
emerge. In this review, we will analyze past studies targeting STAT3 for drug discovery, 
understand possible causes of failure in these studies, and provide potential insights for future 
efforts to overcome these roadblocks.  
Keywords: STAT3 inhibitor, cancer therapeutics, drug discovery, small molecule compounds, 
molecular probes, clinical trials. 
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1. Introduction 
Signal transducer and activator of transcription 3 (STAT3) belongs to a family of Janus 
kinase (JAK)/STAT transcription factors, which regulate responses to extracellular signals 
(Rawlings, Rosler, & Harrison, 2004). In normal tissues/cells, the STAT family proteins become 
transiently activated to relay transcriptional signals from cytokine and growth factor receptors at 
the plasma membrane to the nucleus (J. Bromberg & Darnell, 2000) (see Figure 1A). Stimulation 
of these receptors leads to their autophosphorylation, recruitment of, and activation of JAK. 
Phosphorylation of tyrosine residues on the receptor and JAK leads to the recruitment of STAT3 
by binding to the SH2 domain of STAT3. JAK then phosphorylates STAT3, causing its activation, 
dimerization, and translocation into the nucleus, where it controls transcription of various genes 
important for many normal cellular processes including embryo development, cell differentiation, 
survival, proliferation and angiogenesis (X. Wang, Crowe, Goldstein, & Yang, 2012). Signaling 
by STAT3 under normal physiologic conditions is tightly regulated to maintain a transiently active 
state (Kortylewski & Yu, 2007). However, STAT3 is constitutively activated in many types of 
human cancers including but not limited to colorectal, lung, breast, prostate, liver, and pancreas 
cancers and STAT3 activation associates with poor prognosis of these cancers (Alvarez, Greulich, 
Sellers, Meyerson, & Frank, 2006; Corcoran, et al., 2011; X. Wang, et al., 2012; H. Yu & Jove, 
2004).  
Constitutive activation of STAT3 in cancers results from activation of several oncogenic 
pathways and dysregulation of negative regulators of STAT3 signaling (Leeman, Lui, & Grandis, 
2006). Most frequently, gain-of-function mutations and overexpression of tyrosine kinases, such 
as PDGFR, EGFR, Her2/Neu, IL-6R/gp130, c-Met, and BRC-ABL, leads to the persistent 
activation of STAT3 (Kortylewski & Yu, 2007). The dysregulation of STAT3 downstream target 
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genes, including those involved in survival, proliferation, angiogenesis, and suppression of host 
immune surveillance, have been implicated in tumor initiation and formation (Haura, Turkson, & 
Jove, 2005; H. Yu & Jove, 2004). Aberrant STAT3 activation has also been shown to contribute 
to tumor progression by promoting invasion, metastasis and drug resistance (Al Zaid Siddiquee & 
Turkson, 2008; Lee, et al., 2014; Yue & Turkson, 2009; Zhao, Li, et al., 2016).   
Direct evidence on the oncogenic function of STAT3 comes from the over-expression 
studies of a constitutively-activated STAT3 molecule, STAT3c. It was shown that STAT3c over-
expression transformed human mammary epithelial cells in vitro (Dechow, et al., 2004) and in 
vivo (J. F. Bromberg, et al., 1999). Transgenic over-expression of STAT3c in airway epithelial 
cells also led to lung inflammation and consequently spontaneous lung cancer (Y. Li, et al., 2007). 
Furthermore, use of antisense oligonucleotides significantly impaired the growth of human and 
mouse nucleophosmin-anaplastic lymphoma kinase tumors in xenograft models by inhibiting 
STAT3 expression (Chiarle, et al., 2005). These studies along with other evidences on the multiple 
roles of STAT3 in tumor initiation, progression, resistance, and immunosuppression suggests that 
STAT3 is an attractive target for anticancer drug discovery (Costantino & Barlocco, 2008). Indeed, 
many approaches have been used in an attempt to discover drugs targeting STAT3 over the last 20 
years. However, no STAT3-targeting therapeutics have been approved despite the fact that several 
drugs have entered clinical trials.  In this review, we will provide an in-depth analyses of past 
studies on STAT3 inhibitors that have been studied to date and illustrate possible challenges ahead.  
2. Structure and Activity of STAT3  
In 1998, the crystal structure of STAT3-ß bound to a DNA molecule was solved, offering 
insight into the function and steps necessary for STAT3 to transduce signal into transcription 
activation (Becker, Groner, & Muller, 1998). STAT3 consists of 770 amino acids that constitute 
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six different functional domains (Figure 1B), including amino-terminal domain (NTD), coiled-
coil domain (CCD), DNA-binding domain (DBD), linker domain, SH2 domain, and the carboxyl-
terminal transactivation domain (TAD). The NTD is a conserved sequence, which is essential for 
cooperative binding of STAT proteins to multiple consensus DNA sites (X. Xu, Sun, & Hoey, 
1996). The CCD is critical for recruitment of STAT3 to the receptor and subsequent 
phosphorylation, dimerization, and contains residues essential for nuclear translocation (Ma, 
Zhang, Novotny-Diermayr, Tan, & Cao, 2003; Z. Yu & Kone, 2004; T. Zhang, Kee, Seow, Fung, 
& Cao, 2000). The DBD governs the DNA-binding activity and specificity, allowing recognition 
of and binding to a specific consensus DNA sequence (Horvath, Wen, & Darnell, 1995). The SH2 
domain is required for recruitment and activation as well as dimerization of the STAT3 molecule 
by interacting with phosphorylated tyrosine residues in the opposing subunit (Haan, et al., 1999). 
The linker domain connects the DBD with the SH2 domain and mutational studies have shown 
that it is important in transcriptional activation (Mertens, Haripal, Klinge, & Darnell, 2015). An 
important residue, tyrosine 705, is located in the TAD and becomes phosphorylated upon 
activation of STAT3. Phosphorylation of tyrosine 705 is required for STAT3 monomers to form a 
dimer by binding to the SH2 domain in the opposing subunit (X. Wang, et al., 2012). The STAT3 
dimer can then bind to DNA at its 9-base-pair consensus sequence, TTCCGGGAA, located in the 
promoters of STAT3 target genes (Becker, et al., 1998). An additional phosphorylation site within 
the TAD, serine 727 (Figure 1B), maximizes transcriptional activity and phosphorylation of both 
tyrosine 705 and serine 727 allows the TAD to recruit transcriptional machinery to initiate 
transcription of STAT3 target genes (Wen, Zhong, & Darnell, 1995).  
3. Targeting STAT3 for Therapeutic Development 
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Over the last 20 years, various approaches have been tested to target STAT3 for discovery 
and development of potential therapeutics. These approaches include molecular probes such as 
decoy oligonucleotides, peptides and small molecule inhibitors targeting different domains of 
STAT3 (see Figure 1C for representative inhibitors bound to different domains of STAT3). 
Targeting upstream regulators of STAT3 such as JAK has also been considered. Here, we will 
focus on only approaches and molecules that directly target and bind to the S AT3 protein.  
3.1. Molecular Probes. 
 The first studies that showed promise in the treatment of various cancers by inhibiting 
STAT3 involved molecular probes such as STAT3 dominant negative molecules, decoy 
oligonucleotides, and peptidomimetics (Table 1). In 1996, a dominant negative STAT3 was 
generated by mutating tyrosine 705 to a phenylalanine, which inhibited activation of wild type 
STAT3 (Kaptein, Paillard, & Saunders, 1996). This dominant negative STAT3 has since been 
tested in several different cancer models and was shown to inhibit cancer cell proliferation and 
induce apoptosis (C. L. Chen, et al., 2008; Corvinus, et al., 2005; Niu, et al., 1999; G. Xu, Zhang, 
& Zhang, 2009). Although it is possible to deliver large cDNAs encoding the dominant negative 
STAT3 in a vector in vivo, the efficacy to suppress xenograft tumors is relatively low as shown in 
the study using intratumoral electroinjection (Niu, et al., 1999). Viral vectors for more effective 
delivery of the dominant negative STAT3 into xenograft models have not yet been tested as a gene 
therapy.  
Another molecular probe is a STAT3 decoy oligonucleotide, consisting of a 15-bp duplex 
(Figure 2) representing the genomic element found in c-fos gene promoter, which has been shown 
to inhibit STAT3 activity and proliferation of head and neck cancer cells (Leong, et al., 2003). 
This STAT3-specific decoy was also able to inhibit the growth of xenograft tumors of head and 
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neck (Xi, Gooding, & Grandis, 2005) and lung (X. Zhang, Zhang, Wang, Wei, & Tian, 2007) 
cancer cells via daily intratumoral injection. However, this decoy had no effect on head and neck 
xenograft tumor growth when applied systematically via IV injection (Sen, et al., 2012). This 
observation is also consistent with the previous study where intratumoral injection of this decoy 
into one xenograft tumor did not affect the growth of the counter lateral tumor inoculated on the 
different flank of the same mouse (Xi, et al., 2005). Apparently, this STAT3 decoy is unstable with 
a very short half-life of 1.5 hrs in mouse serum. Nevertheless, a phase 0 clinical trial was conducted 
on treatment of head and neck tumors using this STAT3 decoy with direct intratumoral injection 
(Sen, et al., 2012). While a single injection of the STAT3 decoy did not show toxicity in a dose-
escalating study up to 1 mg/injection, it lowered STAT3 target gene expression in tumor biopsies. 
Its efficacy on the tumor growth or patient outcome of this clinical trial was not reported.  
To eliminate the stability problem, a modified STAT3 decoy was created by closing the 
ends of the 15-bp duplex forming a cyclic structure (Figure 2), which was able to increase its 
stability with a longer half-life (4 hrs) in mouse serum and allowed for systematic delivery (Sen, 
et al., 2012). Although the modified decoy was effective in inhibiting xenograft tumors and STAT3 
target gene expression in mice via intravenous injection, further studies are needed to move 
forward this modified decoy for potential clinical testing. Although STAT3 decoys may 
successfully inhibit xenograft tumor growth and expression of STAT3 target genes, developing 
these decoys into clinically useful therapeutics may face challenges including stability issues for 
systematic use. 
 Since STAT3 activation may require homo-dimerization via binding of the SH2 domain 
from one subunit to the phosphorylated tyrosine 705 in another subunit, it was thought that a 
peptide mimicking the sequence containing phosphorylated tyrosine 705 would be able to bind to 
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the SH2 domain of STAT3 and inhibit its activation and dimerization and, thus, its activity. Indeed, 
many peptidomimetics have been synthesized and tested (Table 1).  
Firstly, a phosphopeptide with a sequence of PpYLKTK from STAT3 was used to inhibit 
the DNA-binding activity of STAT3 but not other STATs such as STAT1 (Turkson, et al., 2001). 
Addition of a membrane-permeabilization sequence (AAVLLPVLLAAP) to this peptide at the 
carboxyl terminus led to a peptide that was able to inhibit STAT3 activity in cells using luciferase 
reporter assay (Turkson, Kim, et al., 2004; Turkson, et al., 2001). However, it is unclear how stable 
this phosphorylated peptide is in cells or in animal models.  
Using alanine-scanning mutagenesis assay, it was found that a minimum of three amino 
acid residues PpYL from the above peptide is sufficient to inhibit STAT3 (Turkson, et al., 2001).  
In a follow-up study with modification of this tripeptide, the newly synthesized peptidomimetics 
have improved activity shown using EMSA (Turkson, Kim, et al., 2004). For example, the 
peptidomimetics ISS 610 with 4-cyanobenzoate replacing the proline residue had 5-fold increase 
in potency for inhibiting STAT3 binding to DNA (Turkson, Kim, et al., 2004). However, despite 
the 5-fold increase, the IC50 is still very high at 42 µM as demonstrated using EMSA. Furthermore, 
although ISS 610 inhibited constitutive activation of STAT3 and cancer cell growth, very high 
concentrations (1 mM) are required to achieve 50% inhibition of cancer cell proliferation in a 3-
day treatment. With such a high cytotoxicity IC50, ISS 610 will likely have difficulty for clinical 
development. 
Another mimetic S3I-M2001 was developed by identifying key hydrogen bonding, 
hydrophobic, and electrostatic interactions between ISS 610 and the STAT3 in the X-ray crystal 
structure (K. A. Siddiquee, et al., 2007). While S3I-M2001 still had a high IC50 value for DNA 
binding (79 µM), it was used in a xenograft model of breast cancer and was shown to inhibit 
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xenograft tumor growth and led to tumor regression. Although these results are promising, further 
optimization is required to improve potency and selectivity and to eliminate potential off-target 
effects. 
In addition to peptidomimetics derived from STAT3 sequence, which have poor affinities 
for STAT3 (Ki=25.9 µM), other peptidomimetics derived from receptor tyrosine kinase sequences 
have been designed recently with improved activity. For example, pYLPQTV, a peptidomimetic 
derived from the phosphorylated gp130 receptor, had a higher affinity for STAT3 than the previous 
peptidomimetics derived from STAT3 (Gomez, et al., 2009). This peptidomimetic was used as a 
starting point for optimization, which led to the development of compound 1 with a high binding 
affinity (Ki=350 nM). Furthermore, it was found that addition of a 7-membered Freidinger lactam, 
to conformationally constrain the peptide, increased the binding affinity with a Ki=190 nM 
(Gomez, et al., 2009). While this compound is effective in binding STAT3in  in-vitro studies, it is 
unable to cross cell membranes to act on intracellular STAT3. Continued development of this 
peptidomimetic led to CJ-1383 with increased cell permeability and a cytotoxicity IC50 of 3.6 µM 
against MDA-MB-468 breast cancer cells (J. Chen, et al., 2010).  
XZH-5 is another peptidomimetic generated using structure-based design focusing on the 
hydrogen bonds that could be formed between the tyrosine 705 and the side pocket in the SH2 
domain  (A. Liu, Y. Liu, Z. Xu, et al., 2011). XZH-5 is cell permeable and prevents STAT3 
phosphorylation, DNA binding, and downregulation of STAT3 target gene expression in multiple 
cancer cells including breast, pancreatic, liver, and rhabdomyosarcoma cells (A. Liu, et al., 2012; 
Y. Liu, et al., 2011). Furthermore, XZH-5 treatment increased the cytotoxicity of 
chemotherapeutic drugs doxorubicin and gemcitabine in cancer cells (A. Liu, et al., 2012). While 
XZH-5 had an increased solubility and selectivity over previous peptidomimetics, it had decreased 
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potency with cytotoxicity IC50 between 15 and 25 µM. New analogues that have better IC50’s, as 
low as 6.5 µM against breast cancer cells, have been identified from modification of XZH-5 as a 
lead (Daka, et al., 2015). While XZH-5 and its analogs show promising results in in-vitro and cell-
based studies, no in-vivo testing have been conducted on these mimetics.  
Peptide aptamers have also been used to inhibit STAT3 by targeting the dimerization 
domain. rS3-PA, for example, is a 20-amino-acid peptide attached to a protein transduction domain 
and a thioredoxin scaffold protein. These attachments  increased stability as well as cellular uptake 
of the peptide (Schoneberger, et al., 2011). rS3-PA was shown to reduce STAT3 phosphorylation 
without any effect on STAT1 phosphorylation (Borghouts, et al., 2012). Additionally, the use of 
rS3-PA together with irinotecan augmented its cytotoxic effect on colon cancer cell lines (Weber, 
et al., 2012). While rS3-PA was successful at reducing Tu-9648 glioma xenograft tumors in mice, 
it had limited systemic stability and its effects were transient and declined a few hours after 
administration (Borghouts, et al., 2012). Nevertheless, increasing the dosing frequency to 3 times 
daily improved tumor growth inhibition (Borghouts, et al., 2012). Clearly, optimization to increase 
the stability of rS3-PA may be required to improve its therapeutic efficacy for further testing.  
Using two-yeast hybrid screening system and the DNA-binding domain (DBD) of STAT3 
as a bait, a peptide aptamer (DBD1, Table 1) was identified as a binder to STAT3 (Nagel-
Wolfrum, et al., 2004). Transient transfection of DNAs encoding this peptide into NIH3T3 or 
mouse melanoma B16 cells inhibited STAT3-dependent luciferase reporter expression and STAT3 
binding to DNA using EMSA. Interestingly, this peptide when fused with a protein transduction 
domain consisting of 9 Arginine residues was able to dose-dependently inhibit proliferation of B16 
cells and induce apoptosis. Although this peptide shows promise as a biological drug targeting the 
DBD of STAT3, no studies have be conducted to test its in-vivo activity.  
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While molecular probes such as peptidomimetics and aptamers, as described above are 
promising strategies in inhibiting STAT3 for development of biological drugs, many challenges 
exist with these approaches including stability and delivery as described above. In addition, these 
molecular probes have low affinity to STAT3 as determined in vitro, which certainly hinders their 
clinical development. The molecular probes including peptides and oligonucleotides may cause 
host immunogenic reactions, which would effectively prohibit their clinical development. The 
peptidomimetics are the first group of inhibitors targeting STAT3 to be studied. Yet, none of these 
mimetics were able to move into phase I clinical testing. Clearly, this approach faces enormous 
challenges to be successfully developed into clinically useful biologic drugs. Novel approaches to 
increase their affinity and perhaps humanization are in dire need to overcome these challenges for 
developing STAT3-targeting biological drugs. 
3.2. Small molecule inhibitors targeting the SH2 domain 
While many issues have arisen in association with developing SH2-domain-targeting 
biologic drugs, as discussed above, other past efforts have focused on developing small molecule 
inhibitors targeting the SH2 domain and many such inhibitors have been identified (Table 2). 
Below we will discuss these SH2-domain-targeting small molecules and how successful they have 
been.  
Stattic was identified from screening a diverse chemical library, containing 17,000 small 
molecules, using a fluorescence polarization-based binding assay targeting the SH2 domain 
(McMurray, 2006; Schust, Sperl, Hollis, Mayer, & Berg, 2006). It was shown to inhibit STAT3 
dimerization, nuclear translocation and activity (Adachi, Cui, Dodge, Bhayani, & Lai, 2012; 
Schust, et al., 2006). Stattic was also shown to inhibit proliferation and induce apoptosis of 
glioblastoma cells with IC50’s at 1-2.5 µM (Villalva, et al., 2011). Similar results were also 
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observed for breast, prostate, and colon cancer cells (Chung, Giehl, Wu, & Vadgama, 2014; Han, 
et al., 2014; Lin, et al., 2013; Lin, Liu, et al., 2011). Additionally, combination treatments of Stattic 
with other chemotherapeutics, such as temozolomide, cisplatin, Herceptin, and radiation increased 
the efficacy of these treatments, leading to increased apoptosis in glioma, head and neck squamous 
cell carcinoma (HNSCC), and breast cancer cells (Adachi, et al., 2012; Chung, et al., 2014; Pan, 
Zhou, Zhang, & Claret, 2013; Villalva, et al., 2011). Stattic has also been tested in several animal 
models such as, HNSCC, esophageal squamous cell carcinoma, colon, prostate and ovarian cancer, 
which showed that Stattic alone reduced tumor growth and has enhanced effect when given in 
combination with radiation and chemotherapeutic treatments (Adachi, et al., 2012; Han, et al., 
2014; Ji, et al., 2013; Spitzner, et al., 2014; Q. Zhang, et al., 2015).  
In-silico screening of a chemical database targeting the SH2 domain of STAT3 led to 
identification of STA-21 (Song, Wang, Wang, & Lin, 2005). The initial studies showed that STA-
21 inhibited DNA binding activity, phosphorylation, dimerization, and transcriptional activity of 
STAT3 (Song, et al., 2005). STA-21 was later used in numerous studies to determine its potential 
in inhibiting cancer cells. Notably, STA-21 inhibited cell growth, viability and induced apoptosis 
through the activation of caspases in many different cancers including breast, bladder, 
rhabdomyosarcoma, and osteosarcoma cell lines with cytotoxicity IC50’s ranging from 12-25 µM 
(C. L. Chen, et al., 2008; C. L. Chen, et al., 2007; Song, et al., 2005). Additionally, mesenchymal 
stem cells co-cultured with glioma cells in different chambers showed a transformation to a 
malignant phenotype, which was abrogated by STA-21 (Cui, Liu, Bai, Tian, & Zhu, 2014).  
STA-21 has also been tested in the treatment of psoriasis and rheumatoid arthritis. Psoriatic 
lesions are characterized by increased levels of cytokines and growth factors as well as an increase 
in activated STAT3 (Miyoshi, et al., 2011). Topical treatment of a mouse model of psoriasis 
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prevented skin lesions (Miyoshi, et al., 2011). Use of STA-21 in the treatment of psoriasis has 
advanced to Phase I/II clinical trials (Miyoshi, et al., 2011; Nadeem, et al., 2017) and has shown 
improvement in psoriatic lesions when administered topically. In rheumatoid arthritis, STAT3 
activation leads to an increase in cytokines that allow the retention of inflammatory cells, which 
attack joints (Alam, Jantan, & Bukhari, 2017; Nowell, et al., 2009). Using mouse models of 
arthritis, it was found that STA-21 could decrease inflammation and inhibit downstream signaling 
pathways known to be involved in rheumatoid arthritis pathology (Ahmad, et al., 2017; Park, et 
al., 2014). While in-vivo models have shown STA-21’s success at treating psoriasis and 
rheumatoid arthritis, it is still unclear if STA-21 is active in vivo in treating cancers. 
Analyses of STA-21 analogues led to identification of LLL3 and LLL12, which have 
smaller molecular weight and improved potency in cancer cell lines with in-vivo antitumor activity 
(Bhasin, Etter, Chettiar, Mok, & Li, 2013; Fuh, et al., 2009; Lin, Hutzen, Li, et al., 2010). LLL12 
contains a sulfonamide, which dramatically increased its potency over STA-21 and LLL3 (see 
Table 2) (Bhasin, et al., 2013). Although further modification of LLL3 improved its in-vitro 
activity, the increase is still far below that of LLL12 (Bhasin, et al., 2013). LLL12 is specific to 
STAT3 and prevented the phosphorylation, nuclear translocation, DNA binding activity of 
STAT3, and decreased expression of STAT3 target genes. LLL12 also blocked IL-6-induced 
STAT3 phosphorylation and led to the induction of apoptosis by increasing the cleavage of 
caspase-3 and PARP in multiple cancer cell lines including breast, pancreatic, colon, and liver 
cancer cells (Ball, Li, Li, & Lin, 2011; Lin, et al., 2012; Lin, Liu, et al., 2011; A. Liu, Liu, Li, Li, 
& Lin, 2011; Y. Liu, Li, Li, & Lin, 2010; Onimoe, et al., 2012; Wei, et al., 2011). LLL12 has been 
tested in multiple tumor models and inhibited xenografts of glioblastoma, hepatocellular 
carcinoma, osteosarcoma, childhood astrocytoma, multiple myeloma, and cancers of prostate, 
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colon, and breast (Bid, et al., 2013; Fuh, et al., 2009; Kroon, et al., 2013; Lin, et al., 2012; Lin, 
Hutzen, Li, et al., 2010; Lin, Liu, et al., 2011; Onimoe, et al., 2012; Zuo, Li, Lin, & Javle, 2015). 
LLL12 also inhibited growth of xenografts of primary multiple myeloma cells from patients who 
were clinically resistant to lenalidomide and bortezomib (Lin, et al., 2012).  
LLL-12 also potently inhibited stem-like cell populations of breast, colon, pancreas and 
prostate cancers. This included a decrease in their viability, tumor sphere-forming capacity and 
clonogenicity (Kroon, et al., 2013; Lin, et al., 2013; Lin, et al., 2016; Lin, Liu, et al., 2011). 
Strikingly, pretreatment with 5 and 10 µM LLL12 of cells derived from a patient with castration 
resistant prostate cancer prior to implantation completely inhibited xenograft tumor growth of 
these cells (Kroon, et al., 2013). Thus, inhibiting STAT3 may help eliminate caner-initiating stem 
cells and help overcome castration resistance.  
While LLL12 shows promising results in preclinical studies, it suffers from low solubility 
and requires high doses for in-vivo studies due to low bioavailability. Additionally, hypoxia-
induced resistance to LLL12 has been observed (J. Xu, et al., 2017). Recently, it was shown that 
stimuli responsive microdroplets containing LLL12 and oxygen could be used to overcome the 
delivery and hypoxic dilemma by releasing oxygen and LLL12 upon stimulation using ultrasound 
(J. Xu, et al., 2017). While this approach could go a long way to solve the limitations of LLL12, it 
has not yet been tested in vivo and its efficacy needs to be validated.  
Using in-silico site-directed fragment-based drug design, a new small molecule inhibitor 
of STAT3, LY5, was made based on known STAT3 inhibitors targeting the SH2 domain with 
LLL12 as the starting point to synthesize fragments (W. Yu, Xiao, Lin, & Li, 2013). LY5 
successfully bound to the SH2 domain, as determined using fluorescence polarization assay, and 
inhibited constitutively-activated STAT3 and IL-6-induced STAT3 activation in several different 
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cell lines including osteosarcoma, medulloblastoma, ewing sarcoma, breast cancer, and 
rhabdomyosarcoma cells (Xiao, et al., 2015; W. Yu, et al., 2013; Zhao, Wang, et al., 2016). It had 
no effect on the phosphorylation of STAT1 induced by IFN-γ (Zhao, Wang, et al., 2016), 
suggesting that LY5 is STAT3 selective over STAT1. LY5 was also able to inhibit nuclear 
translocation, migration and expression of STAT3 downstream target genes in medulloblastoma, 
hepatocellular carcinoma, and colon cancer cell lines (Xiao, et al., 2015; Zhao, Wang, et al., 2016). 
STAT3 phosphorylation is inhibited by LY5 and LY5 suppressed breast and colon xenograft tumor 
growth in mouse models (W. Yu, et al., 2013; Zhao, Wang, et al., 2016). Furthermore, LY5 
combination with cisplatin or radiation caused greater decrease in cell viability of 
medulloblastoma cells than with either single agent/treatment alone (Xiao, et al., 2015). Overall, 
the cytotoxicity IC50 (0.5-1.4 µM) of LY5 is lower than the previous SH2 domain inhibitors and 
it has shown promise at overcoming resistance to a variety of anticancer agents.  
 S3I-201 was also identified via virtual screening targeting the SH2 domain of STAT3 (K. 
Siddiquee, et al., 2007) and it represents the most studied STAT3 inhibitor. Early studies showed 
that S3I-201 disrupted STAT3 dimerization and decreased the DNA-binding and transcriptional 
activity of STAT3 (K. Siddiquee, et al., 2007). S3I-201 also inhibited proliferation, migration, and 
invasion of several cancer cell lines (Bu, Deng, et al., 2015; C. L. Chen, et al., 2007). It was found 
that S3I-201 increased the transcription of caspase genes and may lead to apoptosis of prostate 
cancer and osteosarcoma cell lines through the caspase pathway (Gurbuz, et al., 2014; X. Wang, 
Goldstein, Crowe, & Yang, 2014). S3I-201 also enhanced doxorubicin sensitivity in hepatocellular 
carcinoma cells (Q. D. Hu, et al., 2012). In urothelial carcinoma and bladder carcinoma, S3I-201 
overcame resistance to paclitaxel and cisplatin (W. J. Wang, et al., 2016). Additionally, S3I-201 
sensitized esophageal squamous cell carcinoma to radiation (C. Zhang, et al., 2014). S3I-201 
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enhanced the therapeutic effect of cisplatin, docetaxel, and 5-FU in head and neck squamous cell 
carcinoma by targeting stemloid cells (Bu, Zhao, et al., 2015). When used in a xenograft model of 
HNSCC, at 5 mg/kg every other day, in combination with 10 mg/kg of cisplatin or docetaxel on 
day 14 or combination with 15 mg/kg 5-FU administered day 14 through day 19 inhibited tumor 
growth more than any single agent alone (Bu, Zhao, et al., 2015). Use of other mouse models, 
including models of breast and gastric cancer as well as hepatocellular carcinoma, have shown that 
S3I-201 aids in chemotherapy sensitization and is effective at reducing tumor growth while 
prolonging survival (Bu, Zhao, et al., 2015; Lin, et al., 2009; K. Siddiquee, et al., 2007).  
Several S3I-201 analogs have been created and tested in preclinical models. The first one 
is S3I-201.1066, which was generated using computer-based design and information on the key 
structural elements of S3I-201 involved in binding to the SH2 domain of STAT3 (X. Zhang, et al., 
2010). S3I-201.1066 had improved potency in inhibiting the DNA-binding activity of STAT3 with 
an IC50 of 35 µM compared to 86 µM for the parent compound S3I-201 as determined using 
EMSA (X. Zhang, et al., 2010). These high IC50’s suggest that it may be difficult to compete for 
the SH2 domain in active and dimerized STAT3 in the in-vitro EMSA assay. Nevertheless, S3I-
201.1066 treatment resulted in reduced STAT3 activity, expression of STAT3 downstream target 
genes, and inhibited survival of cancer cells and xenograft tumor growth. Interestingly, there is a 
~3-fold difference in cytotoxicity IC50 of S3I-201.1066 between cancer cells and MEF cells that 
lack STAT3, suggesting that it has a therapeutic window. However, despite the improvement of 
S3I-201.1066 in inhibiting STAT3 activity over S3I-201, the cytotoxicity IC50 of S3I-201.1066 
for cancer cells is >37 µM, making it a less likely candidate for clinical development. 
Additional effort has also been made to further optimize S3I-201 and S3I-201.1066 to 
improve potency (Urlam, et al., 2013). which led to the identification of several analogues 
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including S3I-1757 (X. Zhang, et al., 2013), BP-5-087 (Eiring, et al., 2015), BP-1-102 (Resetca, 
Haftchenary, Gunning, & Wilson, 2014; X. Zhang, et al., 2012), SH-4-54, SH-5-07 (Haftchenary, 
et al., 2013), and PG-S3-001 (Arpin, et al., 2016). S3I-1757 is a novel non-sulfonamide containing 
salicylic acid, which inhibited STAT3 dimerization and nuclear translocation. It also inhibited 
anchorage independent growth, invasion and migration of human breast and lung cancer cell lines. 
BP-5-087 differs from S3I-201.1066 by substitution of a 2-methylbenzyl group on the 
sulfonamide group (Eiring, et al., 2015). This modification prevented STAT3 binding to a 
phosphotyrosine peptide with an IC50 of 5.6 µM. Furthermore, BP-5-087 was tested in primary 
chronic myeloid leukemia cells with BCR-ABL1 tyrosine kinase inhibitor resistance and it 
restored sensitivity to treatment and reduced colony formation ability and survival (Eiring, et al., 
2014; Eiring, et al., 2015).  
BP-1-102 contains a pentafluorobenzene in place of the 3-methylbenzene of S3I-201.1066. 
The substitution of pentafluorobenzene decreased the IC50 for DNA binding down to 6.8 µM with 
an improved selectivity to STAT3 over STAT1 and STAT5 (X. Zhang, et al., 2012). BP-1-102 
had a significant impact on growth, survival, migration, and invasion of tumor cells with 
constitutively active STAT3. BP-1-102 is orally available and inhibited human breast, lung and 
colon tumor growth in xenograft models (De Simone, et al., 2015; X. Zhang, et al., 2012).  
Increased potency was achieved by the development of SH-4-54 and SH-5-07 with 
cytotoxicity IC50’s ranging 66-235 nM and 195-1120 nM in brain cancer stem cells, respectively 
(Haftchenary, et al., 2013). SH-4-54 was achieved by removing the hydroxyl group from the 
salicylic acid forming benzoic acid while SH-5-07 exchanged the salicylic acid for an N-
hydroxylamine (Haftchenary, et al., 2013). These compounds were effective at suppressing 
STAT3 phosphorylation and transcriptional activities. They are permeable to the blood-brain 
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barrier and inhibited growth of glioblastoma cells as well as breast cancer in in-vivo mouse models 
(Haftchenary, et al., 2013). In-vivo PK/PD studies have shown accumulation of SH-4-54 in the 
brain and its ability to target STAT3 with limited side effects. Furthermore, PG-S3-001, a 
derivative of SH-4-54, was shown to be able to inhibit proliferation of pancreatic cancer cells using 
a 3D culture system with an IC50 of 15.2 µM and growth of patient-derived xenograft tumors 
(Arpin, et al., 2016).  
 STX-0119, another STAT3 inhibitor targeting the SH2 domain, was also identified using 
in-silico screening (Matsuno, et al., 2010). STX-0119 treatment of lymphoma cell lines led to a 
significant growth inhibition and induction of caspase cleavage (Ashizawa, et al., 2011). Oral 
administration of STX-0119 led to reduction in STAT3 target gene expression as well as induction 
of apoptosis in xenograft tumors from lymphoma cell line SCC3. STX-0119 has also been used to 
treat glioblastoma by targeting the stem cell populations (Ashizawa, et al., 2013). While STX-
0119 had little effect on glioblastoma tumor growth derived from U87 cells, it was able to inhibit 
growth of xenograft tumors of temozolomide-resistant U87 cells (Ashizawa, et al., 2014). While 
the finding on STX-019 inhibition of temozolomide resistant U87 xenograft tumors is exciting, it 
is not clear why it had no effect on the parental U87 xenograft tumors and if the effect on 
temzolomide resistant U87 tumors was STAT3-dependent. 
Additionally, a natural product, curcumin, has also been shown to inhibit STAT3 signaling 
(Zhao, Liu, & Liang, 2013). However, due to its low bioavailability and being quickly 
metabolized, different curcumin analogs have been synthesized to increase its bioavailability and 
stability (Lin, Hutzen, Zuo, et al., 2010; Wei, et al., 2011; Zhao, et al., 2013). Two such analogs, 
FLLL31 and FLLL32, had the 2 hydrogens in the center of curcumin replaced with methyl groups 
and a spiro-cyclohexyl ring, respectively, and have a 3,4-dimethoxy substitute, which helped 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
increase stability (Lin, Hutzen, Zuo, et al., 2010). Both FLLL31 and FLLL32 inhibited STAT3 
phosphorylation, DNA-binding activity in vitro, colony formation and cell invasion as well as 
induced apoptosis of pancreatic and breast cancer cells (Lin, Hutzen, Zuo, et al., 2010). Further 
study of FLLL32 showed that it potently caused apoptosis of melanoma, multiple myeloma, 
osteosarcoma, rhabdomyosarcoma, renal cell carcinoma, glioblastoma, liver and colorectal cancer 
cell lines at micromolar concentrations (Bill, et al., 2010; Bill, et al., 2012; Fossey, et al., 2011; 
Lin, Deangelis, et al., 2010; Lin, Fuchs, et al., 2011; Onimoe, et al., 2012; Wei, et al., 2011). In 
colon and pancreatic cancers, FLLL32 reduced cell viability of the stem-like cell population, 
decreased tumorsphere formation and expression of STAT3 downstream target genes, and induced 
caspase dependent apoptosis in colon cancer stem-like cells (Lin, Fuchs, et al., 2011; Lin, et al., 
2016). Use of FLLL32 has been shown to decrease growth of xenograft osteosarcoma and breast 
tumor (Onimoe, et al., 2012; Yan, et al., 2015). FLLL32 significantly reduced tumor growth and 
tumor vascularity in a chicken embryo xenograft model of pancreatic cancers (Lin, Hutzen, Zuo, 
et al., 2010). However, whether FLLL31 and FLLL32 directly bind to the SH2 domain requires 
further studies.  
Most recently, a synthetic derivative of a natural product bisindolylmaleimide alkaloid, 
BMA097, was shown to directly bind to the SH2 domain and inhibit STAT3 dimerization and 
activation (X. Li, et al., 2018). It is effective in suppressing breast cancer cell growth with IC50’s 
ranging 0.9-3.9 µM against different cell lines. It also inhibited growth of breast xenograft tumors 
and induced spontaneous apoptosis. The structure-activity relationship analysis revealed that the 
hydroxymethyl group in the 2,5-dihydropyrrole-2,5-dione is important for the STAT3-inhibitory 
activity. Although other BMAs have previously been shown to inhibit PKC, the synthetic 
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analogue, BMA097, does not appear to have this activity. Nevertheless, whether BMA097 has 
other potential targets remains to be determined.  
Finally, several FDA-approved drugs have also been shown to inhibit STAT3 signaling 
and therefore, may be repurposed. These drugs include  celecoxib (H. Li, et al., 2011), 
piperlongumine (Bharadwaj, et al., 2015), artesunate (Ilamathi, Santhosh, & Sivaramakrishnan, 
2016; C. Kim, Lee, Kim, Sethi, & Ahn, 2015), nifuroxazide (Nelson, et al., 2008; Yang, et al., 
2015), and niclosamide (Ren, et al., 2010). While celecoxib, piperlongumine, and artesunate have 
been shown to bind directly to STAT3, possibly at the SH2 domain, nifuroxazide was shown to 
inhibit the upstream JAK autophosporylation and niclosamide was shown to inhibit STAT3 
phosphorylation on Tyr705 but does not bind to the SH2 domain. Although more detailed studies 
are required to understand if and how effective these drugs are in inhibiting STAT3 activity and 
signaling, these approved drugs may prove to be an interesting approach and a faster way to 
translate into clinical testing.  
In summary, many small molecule inhibitors targeting the SH2 domain of STAT3 have 
been identified with some having in-vivo activity and the list of such inhibitors continues to grow. 
Although some of these inhibitors have been shown to bind directly to the SH2 domain, many 
others are only predicted to bind to the SH2 domain based on computational modeling and 
inhibition of STAT3 phosphorylation. Some studies lack evidence to eliminate the possibility that 
the inhibitor may inhibit JAK2, which results in reduced STAT3 phosphorylation, raising concerns 
on specificity. Another common issue of these inhibitors is their high cytotoxicity IC50, which 
would preclude them from further clinical development. Although medicinal chemistry has been 
conducted to optimize some of these inhibitors, the improvement appears to be limited and none 
has resulted in a lead with cytotoxicity IC50 in the low nanomolar range. Clearly, future studies 
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may need to focus on optimizing the existing inhibitors to generate more active derivatives. Only 
when SH2 domain-targeting STAT3 inhibitors that are more active and more selective than those 
described above are identified, will there be clinically testable inhibitors (see below). However, it 
is concerning that most of SH2 domain inhibitors have high cytotoxicity IC50, which raises a 
possibility that the SH2 domain may be difficult to target. It is also noteworthy that natural 
products may be a rich resource to discover potential STAT3 inhibitors targeting its SH2 domain. 
However, caution should be considered when testing some of these natural products such as 
curcumin, which may be promiscuous with limited selectivity. 
3.3. SH2 domain inhibitors in clinical trials 
As described above, many SH2 domain inhibitors have shown promise in laboratory 
studies. However, only a few have successfully made it into clinical trials (Table 3). While STA-
21 has been tested for the treatment of psoriatic lesions as discussed above (Miyoshi, et al., 2011), 
it has yet to be tested clinically for cancer treatment in systematic use.  
Two of the most promising STAT3 inhibitors in clinical trials were OPB-31121 and OPB-
51602. These compounds, which were thought to target the SH2 domain, are very potent and have 
been shown to have antitumor effects in several different cancers in preclinical in-vitro and in-vivo 
studies (Brambilla, et al., 2015; Hayakawa, et al., 2013; M. J. Kim, et al., 2013). They both have 
completed Phase I/II clinical trials for multiple cancers including advanced solid tumors, non-
Hodgkin’s lymphoma, multiple myeloma, hepatocellular carcinoma, and hematologic 
malignancies (Bendell, et al., 2014; Ogura, et al., 2015; Oh, et al., 2015; Okusaka, et al., 2015; 
Wong, et al., 2015). While initial studies for OPB-31121 showed feasibility in inhibiting STAT3 
and having antitumor effects, clinical trials in hepatocellular carcinoma showed minimal antitumor 
activity, poor pharmacokinetic properties, and peripheral nervous system toxicity (Okusaka, et al., 
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2015). OPB-51602 only demonstrated some antitumor activity in non-small cell lung cancer but 
not in hematologic malignancies (Ogura, et al., 2015; Wong, et al., 2015). The clinical trials were 
terminated for both of these inhibitors due to poor pharmacokinetic properties and intolerability. 
These inhibitors require further optimization to improve pharmacokinetic properties and to limit 
observed toxicity. 
Pyrimethamine, originally identified as an antimalarial drug by inhibiting dihydrofolate 
reductase, is currently in phase I/II clinical trial in the treatment of chronic lymphocytic leukemia 
and small lymphocytic leukemia (https://clinicaltrials.gov/ct2/show/NCT01066663) after being 
identified as a potential STAT3 inhibitor via screening a library of 1120 drugs that are known to 
be safe in human using cell-based STAT3-dependent luciferase reporter assay (Takakura, et al., 
2011). Pyrimethamine inhibited tyrosine phosphorylation of STAT3 without inhibiting its 
upstream kinase JAK2 and, thus, was also thought to bind to the SH2 domain of STAT3. Recent 
pre-clinical studies have shown that pyrimethamine may be effective at treating glioblastoma and 
acute myeloid leukemia (Baritchii, et al., 2016; Sharma, et al., 2016). Very recently, a xenograft 
mouse model of breast cancer showed reduction in STAT3 activation, tumor growth, and in 
inflammation following pyrimethanmine treatments (Khan, et al., 2018). There was also 
indications of increased cytotoxic granule release by tumor infiltrating CD8+ cells in this model 
as indicated by Lamp1 expression. However, it is yet to be shown whether the anticancer activity 
of pyrimethamine is via inhibiting STAT3, dihydrofolate reductase or both.  
Recently, another STAT3 inhibitor targeting its SH2 domain, C188-9, has entered phase I 
trial in treating advanced cancers (https://clinicaltrials.gov/ct2/show/NCT03195699). C188-9 was 
a more effective analogue of one of the hit inhibitors derived from in-silico screening of a chemical 
library targeting the SH2 domain of STAT3 (Redell, Ruiz, Alonzo, Gerbing, & Tweardy, 2011; 
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X. Xu, Kasembeli, Jiang, Tweardy, & Tweardy, 2009). C188-9 was able to bind directly to STAT3 
with a KD of 4.7 nM (Bharadwaj, et al., 2016) and the binding prevents STAT3 phosphorylation, 
induces apoptosis, and inhibits xenograft tumor growth (Bharadwaj, et al., 2016; Jung, et al., 2017; 
Lewis, et al., 2015; Redell, et al., 2011). C188-9 has a good safety profile and good 
pharmacokinetic properties in mice, rats and dogs (Jung, et al., 2017), providing the required basis 
for phase I testing. 
Moving some of the SH2 domain inhibitors into clinical trials is very encouraging despite 
the possibility that these inhibitors may never gain FDA approval. In addition to the potential 
toxicity and poor pharmacokinetics in the case of OPB-31121 and OPB-51602, other possible 
issues may need to be considered in future clinical trials in order to ensure its success. One such 
consideration should be stratifying patient population for clinical trials and testing specific cancer 
types that are driven by STAT3 activation. For example, activating mutations in the SH2 domain 
have been identified that associates with large granular lymphocytic leukemia with 40% mutation 
rate (Koskela, et al., 2012). Similar mutations in the SH2 domain have also been identified in 
inflammatory hepatocellular adenomas (Pilati, et al., 2011). While it remains to be determined, 
these somatic mutations may affect the binding of the SH2 domain inhibitors to STAT3 and reduce 
the efficacy of these inhibitors. The fact that OPB-51602 had no effect on hematological 
malignancies (see above) is consistent with this speculation. Thus, further study of these mutations 
and identifying patients with these mutations will likely benefit clinical testing of the SH2 domain-
targeting STAT3 inhibitors and benefit patients with precision use.  
3.4. Small molecule inhibitors targeting the DNA-binding domain (DBD) 
The SH2 domain has largely been the focus in drug discovery targeting STAT3. However, 
successes of the past studies on SH2 domain inhibitors have been limited as discussed above. 
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Furthermore, it has been shown that the import of STAT3 into the nucleus and binding to DNA 
can occur independent of its phosphorylation status (L. Liu, McBride, & Reich, 2005; Nkansah, et 
al., 2013). This observation indicates that SH2 domain inhibitors may not be sufficient to fully 
inhibit STAT3 function, which may contribute to the limited success of these inhibitors. 
Interestingly, few studies have been conducted to target the other domains of STAT3 (Figure 1). 
Of these other domains of STAT3, only the DBD has been tested for discovery of small molecule 
inhibitors (Table 4). In general, the DBD of transcription factors are considered “undruggable”. 
This is due to the fact that DBDs are flat with similarities among different isoforms of the same 
transcription factor family and, thus, potentially limiting selectivity.  
A class of platinum compounds including IS3-295, CPA-1, CPA-7, and platinum (IV) 
tetrachloride has been found to block the DNA-binding activity of STAT3, inhibit cell growth, and 
induce apoptosis while having no effect on cells that did not have persistent STAT3 activation 
(Turkson, et al., 2005; Turkson, Zhang, et al., 2004). These compounds had better inhibitory 
profiles than the peptide inhibitor as described above. Of these compounds only CPA-7 has been 
tested in in-vivo models. CPA-7 had antitumor activity in prostate, colon, and glioma mouse 
xenograft models (Assi, et al., 2014; Liang, et al., 2016; Turkson, Zhang, et al., 2004; L. Zhang, 
et al., 2009). However, its inability to cross the blood brain barrier limits its use in the treatment 
of tumors in the central nervous system. While cursory toxicology studies have been performed 
on tumor-bearing animals, a full assessment is needed before CPA-7’s clinical relevance can be 
determined.   
A natural product, Galiellalactone, was identified to inhibit the DNA-binding activity of 
STAT3 while screening for compounds that inhibited IL-6-induced gene expression (Weidler, 
Rether, Anke, & Erkel, 2000). Using biotinylated Galiellalactone as a probe in combination with 
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MS analysis, it was found that the DBD of STAT3 was likely the binding site for Galiellalactone 
(Don-Doncow, et al., 2014). The cysteine residues Cys-367, Cys-468 and Cys-542 in the linker 
and DBD of STAT3 were covalently modified by Galiellalactone since it is a cysteine-reactive 
Michael acceptor (Don-Doncow, et al., 2014; Garcia, et al., 2016). Galiellalactone has been shown 
to reduce tumor size and to reduce metastatic spread in prostate cancer cell lines and xenograft 
mouse model (Canesin, et al., 2016; Hellsten, et al., 2008). Furthermore, Galiellalactone was able 
to reduce the number of ALDH+ cells, or stem-like cells, in DU145 xenograft tumors (Hellsten, 
Johansson, Dahlman, Sterner, & Bjartell, 2011). However, the bioavailability of orally 
administered Galiellalactone is low and the in-vivo studies required IP injection. To increase the 
oral bioavailability of Galiellalactone, a prodrug, GPA512, was created by adding an N-Acetyl L-
cysteine methyl ester to the thiol of Galiellalactone (Escobar, et al., 2016). GPA512, at an oral 
dose of 40 mg/kg daily, inhibited growth of prostate xenograft tumors, which was similar to the 
outcomes observed when Galiellalactone was used via intraperitoneal injection (Escobar, et al., 
2016). Thus, GPA512 may function as an orally available prodrug of Galiellalactone. However, 
Galiellalactone has been shown to interrupt other signaling pathways such as NF-kB and TGF-ß 
and it can bind several other target proteins due to its Michael acceptor activity (Don-Doncow, et 
al., 2014). This lack of specificity may prove to be an issue during its future development. 
While curcumin and a few of its analogues were discussed above to target the SH2 domain, 
HO-3867, another curcumin analog, has been suggested to bind to the DBD of STAT3 (Rath, et 
al., 2014). HO-3867 has been tested in several cancer cell lines including breast, colon, head and 
neck, pancreas, liver, lung, ovarian and prostate cancer cell lines. HO-3867 has also been tested in 
an ovarian xenograft mouse model (Selvendiran, et al., 2011; Selvendiran, Ahmed, Dayton, 
Kuppusamy, et al., 2010). In these studies, HO-3867 had preferential cytotoxicity towards cancer 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
cells versus non-cancerous cells (Selvendiran, Ahmed, Dayton, Kuppusamy, et al., 2010). 
Furthermore, STAT3 was thought to mediate the cellular effect of HO-3867 as determined by 
overexpressing or knocking down STAT3 (Tierney, et al., 2012). In an ovarian xenograft mouse 
model, it was shown that HO-3867 inhibited tumor growth, angiogenesis, and metastasis (Saini, 
et al., 2017; Selvendiran, et al., 2011). However, it was also found that HO-3867 decreased the 
phosphorylation status of STAT3, which indicates that it may not bind to the DBD of STAT3. 
Interestingly, HO-3867 has also been shown to increase FASN degradation, inhibit JAK activation, 
and produced reactive oxygen species (Y. Hu, et al., 2017; Selvendiran, Ahmed, Dayton, Ravi, et 
al., 2010; Selvendiran, Tong, et al., 2010). These findings further highlight the promiscuity of 
curcumin and its analogues and, thus, they are unlikely specific to STAT3.  
Using an improved in-silico screening method, a small molecule inhibitor, inS3-54, was 
identified targeting the DBD of STAT3 (Huang, et al., 2014). inS3-54 selectively inhibited the 
DNA-binding activity of STAT3 both in vitro and in situ but had no effect on the phosphorylation 
of STAT3.  Additionally, in-silico screening showed that inS3-54 does not bind to STAT1 and is 
selective for the DBD of STAT3, which was confirmed using EMSA. inS3-54 also effectively 
inhibited IL-6-induced activity of STAT3 and proliferation, migration, and invasion of both breast 
and lung cancer cell lines (Huang, et al., 2014). 
Further investigation of inS3-54 analogues led to identification of a pharmacophore as 
shown in Figure 3A (Huang, et al., 2016). Of the analogues tested, inS3-54A18, A26, and A69 
(Figure 3B) were identified to be more active than the parent inS3-54. Interestingly, the 
cytotoxicity IC50 of all these three analogues negatively associates with the level of activated 
STAT3 in different cell lines tested (Figure 3C).  InS3-54A18 (A18) was selected as a lead 
compound based on its enhanced properties in solubility, specificity and pharmacology. It has 
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IC50s ranging from 1.8 to 5.6 μM for cancer cells and from 4.0 to 12.0 μM for non-cancer cells. 
A18 not only inhibited the constitutive and IL-6-stimulated expression of STAT3 downstream 
target genes, it also effectively inhibited lung xenograft tumor growth and metastasis with little 
adverse effect on animals. Importantly, it was also shown, using pull-down assay of purified 
recombinant STAT3 and immobilized compounds, that A18 directly binds to the DBD of STAT3. 
Thus, A18 is a potential candidate for further development as anticancer therapeutics targeting the 
DBD of human STAT3. 
Recently, pyrimidinetrione and its derivatives have been identified as potential STAT3 
DBD inhibitor by screening 300 compounds using EMSA and Sitemap program analyses (Shan 
Sun, 2017). The pyrimidinetrione derivatives were shown to decrease cancer cell viability and 
growth but had little effect on STAT3 null MEF cells. Thus, the pyrimidinetrione compounds may 
be used to help design future STAT3 DBD inhibitors.  
As stated above, relatively few studies have been focused on targeting domains other than 
the SH2 domain. Although progress in targeting the DBD of STAT3 has been made recently, 
developing inhibitors targeting DBD will likely face challenges as well. Similar to the SH2 
domain, as discussed above, somatic mutations have also been identified in the DBD of STAT3. 
One such mutation is H410R, which activates STAT3 without upstream stimulation (Andersson, 
et al., 2016). While the histidine to arginine mutation was thought to increase hydrophilicity of the 
DBD and STAT3 binding to DNA, it may also prohibit binding of STAT3 inhibitors to the DBD. 
Several dominant negative mutations in the DBD have also been identified and associated with 
hyper-IgE syndrome (Minegishi, et al., 2007). Although it is unknown if these mutations could 
occur in human cancer cells, such dominant negative mutations will likely render ineffectiveness 
of any STAT3-targeting inhibitors in cancer treatment.  
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4. Conclusions and Perspectives 
It has been clearly shown and accepted that constitutive STAT3 activation gives tumor 
cells a survival advantage. Targeting STAT3 within tumor cells may prove to be successful in 
treating cancers and sensitizing them to current chemotherapeutics. However, while many different 
STAT3 inhibitors have been identified, with few in clinical trials, there are currently no approved 
drugs targeting STAT3. Based on the above discussion and history of development, it is likely that 
we will face many challenges ahead in developing STAT3 targeting inhibitors. 
The vast majority of past STAT3 inhibitors, as discussed above, targeted the SH2 domain 
with few targeting other domains of the protein. Targeting the SH2 domain has limited success 
due to insufficient inhibition of STAT3. STAT3 has been shown to translocate into the nucleus 
and bind to DNA even without Tyr705 phosphorylation. With new approaches being developed 
and the increasing studies of targeting other domains, such as the DBD of STAT3, novel inhibitors 
with higher affinity to STAT3 and lower cytotoxic IC50’s may emerge and enter into clinical trials. 
Testing additional FDA-approved drugs for their potential in inhibiting STAT3 may result in novel 
inhibitors for repositioning and quick translation into clinical testing for treating human cancers 
by targeting STAT3.  
One of the major problems with STAT3 inhibitors, as discussed above, is their high 
cytotoxic IC50 values, which prohibits further development. Clearly, medicinal chemistry work is 
needed to optimize some of these promising inhibitors. It is also noteworthy that the inhibitors 
with high affinity to STAT3 often show adverse effects such as fatigue, diarrhea, infection, and 
periphery nervous system toxicities. These adverse effects may be associated with the 
physiological function of STAT3 in normal tissues and, thus, result in STAT3-specific toxicity. 
For example, it has been shown previously that tissue-specific conditional STAT3 inactivation 
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leads to enterocolitis and Crohn’s disease-like pathogenesis (Alonzi, et al., 2004; Kortylewski, et 
al., 2005; Welte, et al., 2003). Thus, consideration and use of targeted delivery for high affinity 
STAT3 inhibitors may help avoid or eliminate these adverse effects in future direction of research 
on developing STAT3 inhibitors.  
Another major potential problem is somatic mutations in STAT3, which may inhibit the 
binding of inhibitors to STAT3 and cause ineffectiveness of these inhibitors as discussed above. 
Considering that these mutations occur at a rate of 40% in large granular lymphocytic leukemia, it 
is conceivable that the outcome of clinical studies could be affected by these mutations should they 
prohibit inhibitor binding to STAT3. Unfortunately, no studies have addressed if these mutations 
affect inhibitor binding to STAT3. Understanding the relationship between these somatic 
mutations and STAT3 inhibitor efficacy in future studies will be very important for developing 
effective STAT3-targeting drugs for precision use. 
Tumor heterogeneity is another potential area of research that deserves thoughtful 
consideration in developing STAT3 inhibitors. Cancer is a dynamic disease and constantly changes 
during the development of this disease, resulting in diversity and heterogeneity (Dagogo-Jack & 
Shaw, 2018). Analysis of several cell lines have revealed cell-cell heterogeneity in STAT3 
activation in a cell population (Gough, et al., 2014). Recently, it was discovered that oncogenically 
transforming normal human bronchial epithelial cells resulted in tumor cells with heterogeneity of 
two major mutually exclusive subpopulations (Deb, et al., 2017). One subpopulation had 
upregulated STAT3 activation and was sensitive to STAT3 inhibitors while the other had 
downregulation of SMAD2/3 signaling and were resistant to STAT3 inhibitor treatments. It is also 
tempting to speculate that tumor heterogeneity with cells expressing drug efflux pumps may cause 
resistance to STAT3 inhibitors. Thus, tumor heterogeneity will likely influence the outcome of 
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STAT3 inhibitor treatment. Combination of STAT3 inhibitors with other agents may help 
overcome these problems as demonstrated by Deb et al (Deb, et al., 2017), who showed that 
combining STAT3 and BCL6 inhibitors more effectively eliminated their heterogenic cancer cells 
than any single treatment alone. Future studies should be conducted to determine other mutually 
exclusive pathways from STAT3 in order to develop therapeutic combinations. 
Our lack of understanding of cross-talks between signaling pathways and compensatory 
pathways may have also contributed to the past failure in developing STAT3 inhibitors. Indeed, 
combinations of STAT3 inhibitors with other targeted therapeutics have shown promises. For 
example, crosstalk between MEK and STAT3 activation has been observed to lead to resistance 
to MEK inhibitors in K-ras mutant pancreatic and colon cancer cells and combination of STAT3 
inhibitor LY5 with MEK inhibitor Trametinib had synergistic effect on these cells both in vitro 
and in vivo (Zhao, et al., 2015). STAT3 has also been shown to contribute to EGFR inhibitor 
resistance and combination of STAT3 inhibitor S3I-201 with EGFR inhibitor overcame the 
resistance and increased the anti-proliferative effect (W. Chen, et al., 2012). Thus, combination 
therapies may help overcome the challenges created by signaling cross-talk and compensatory 
pathways. Additional research into how these pathways interact will help determine the best course 
of actions and the most promising combinations.  
Another line of future research direction with potentials is combination of STAT3 
inhibitors with immunotherapeutics. Immune surveillance plays a significant role in eliminating 
tumor cells. Activation of STAT3 in cancer cells increases expression of immunosuppressive 
factors which leads to suppression of immune cells (H. Yu, Kortylewski, & Pardoll, 2007). This 
immunosuppression is maintained in immune cells by STAT3 activation. Considering the function 
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and activity of STAT3 in immune evasion of cancer cells, STAT3 activation may be an effective 
way to both target tumor cells and stimulate the immune system to eliminate tumor cells.  
In summary, while we have come a long way in understanding and targeting STAT3 for 
drug discovery and development, there is still no FDA approved STAT3 inhibitor. This may be 
due to a lack of full inhibition of STAT3 while targeting the SH2 domain, lack of understanding 
of signaling cross talk, and adverse events related to STAT3-specific activity in normal tissues. 
Recently, targeting other domains of STAT3 as an alternative approach began to attract attention 
to overcome the limitations of SH2 targeting molecules. Further understanding the relationship 
between tumor heterogeneity and STAT3 signaling, cross-talks between STAT3 and other 
signaling pathways, STAT3 dependency and specific cancer types, as well as the effect of somatic 
mutations on cellular response to STAT3 inhibitors will all likely help successfully develop 
STAT3 inhibitors.  This information will likely also contribute future patient stratification and 
precision use of STAT3 inhibitors in the clinical setting. Finally, consideration of tumor site 
delivery of STAT3 inhibitors using special vehicles will likely help avoid STAT3-specific toxicity 
in normal tissues.  
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Table 1. Molecular probes targeting STAT3 
Name  Structure/Sequene Activity Remarks References 
Mimetic 
derived from 
STAT3  
PpYLKTK 
IC50=235 µM  
(DNA binding) 
  
(Turkson, Kim, et al., 2004; 
Turkson, et al., 2001) 
Minimum 
required 
mimetic 
sequence  
PpYL 
IC50=182 µM  
(DNA binding) 
  
 (Turkson, Kim, et al., 2004; 
Turkson, et al., 2001) 
Mimetic 
derived from 
GP130  
pYLPQTV 
Kd=35 nM 
(Binding affinity) 
   (Gomez, et al., 2009) 
ISS610 
 
IC50=42 µM 
(DNA binding) 
  
 (Turkson, Kim, et al., 
2004) 
S3I M2001 
 
IC50=79 µM 
(STAT3 dimerization) 
IC50=50-100 µM  
(cytotoxicity) 
Effective on 
breast 
xenograft 
tumors  
 (K. A. Siddiquee, et al., 
2007) 
Compound 1 
 
Ki=350 nM 
(Phosphopeptide 
Binding) 
   (Gomez, et al., 2009) 
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Compound 3 
 
Ki=190 nM 
(Phosphopeptide 
Binding) 
  (Gomez, et al., 2009)  
CJ1383 
 
Ki=950 nM 
(Phosphopeptide 
binding) 
IC50=3.6-11.2 µM 
(Cytotoxicity) 
  (J. Chen, et al., 2010) 
XZH-5 
 
IC50=15-25 µM 
(Cytotoxicity) 
 
(Daka, et al., 2015; A. Liu, 
et al., 2012; A. Liu, Y. Liu, 
Z. Xu, et al., 2011; Y. Liu, 
et al., 2011) 
rS3-PA N-VRH SAL HMA VGP LSW PAR VS-C   
Effective on 
xenograft 
glioma 
 (Borghouts, et al., 2012; 
Schoneberger, et al., 2011; 
Weber, et al., 2012) 
DBD1 PLTAVFWLIYVLAKALVTVC 
IC50=270 nM 
(Cytotoxicity) 
 
 (Nagel-Wolfrum, et al., 
2004) 
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Table 2. Small molecule inhibitors targeting the SH2 domain of STAT3 
Drug Structure IC50 Remarks References 
STATTIC 
 
IC50=5.1 µM 
(Phosphopeptide 
binding)  
IC50=1-4 µM 
(Cytotoxicity)  
Effective on 
xenograft HNSCC, 
esophageal squamous 
cell carcinoma, 
ovarian, colorectal, 
and prostate cancers  
 (Agudelo-Garcia, et al., 
2011; Cardoso, et al., 
2012; Chung, et al., 2014; 
Han, et al., 2014; Ji, et al., 
2013; Lin, et al., 2013; 
Lin, et al., 2016; Lin, Liu, 
et al., 2011; McMurray, 
2006; Pan, et al., 2013; 
Schust, et al., 2006; Shen, 
Gu, Jian, & Qi, 2013; 
Souissi, et al., 2011; 
Spitzner, et al., 2014; 
Villalva, et al., 2011) 
STA-21 
 
IC50=12-20 µM 
(Cytotoxicity)  
Effective on psoriatic 
lesions in mouse 
models 
(Ahmad, et al., 2017; C. 
L. Chen, et al., 2007; Cui, 
et al., 2014; Miyoshi, et 
al., 2011; Nadeem, et al., 
2017; Park, et al., 2014; 
Song, et al., 2005)  
LLL3 
 
IC50 = 6.8-11.5 µM 
(Cytotoxicity) 
Effective on 
xenograft 
glioblastoma 
 (Bhasin, et al., 2013; 
Fossey, et al., 2009; Fuh, 
et al., 2009) 
LLL12 
 
IC50=0.11-6 µM 
(Cytotoxicity) 
Effective on 
xenograft 
glioblastoma, 
multiple myeloma, 
osteosarcoma, 
astrocytoma, 
hepatocellular 
carcinoma, breast, 
and prostate cancers 
 (Ball, et al., 2011; 
Bhasin, et al., 2013; Lin, 
et al., 2012; Lin, et al., 
2013; Lin, Hutzen, Li, et 
al., 2010; Lin, et al., 2016; 
Lin, Liu, et al., 2011; A. 
Liu, Y. Liu, P. K. Li, et 
al., 2011; Y. Liu, et al., 
2010; Onimoe, et al., 
2012; Wei, et al., 2011; J. 
Xu, et al., 2017; Zuo, et 
al., 2015) 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
LY5 
 
IC50=0.5-1.4 µM 
(Cytotoxicity) 
Effective in xenograft 
breast, colon, and 
pancreatic cancers 
 
(W. Yu, et al., 2013; 
Zhao, Wang, et al., 2016)  
S3I-201 
 
IC50=85-150 µM 
(Cytotoxicity) 
Effective on 
xenograft HNSCC, 
hepatocellular 
carcinoma, breast, 
and gastric cancers 
(Q. D. Hu, et al., 2012; 
Lin, et al., 2009; K. 
Siddiquee, et al., 2007)  
S3I-1757 
 
IC50=13.5 µM 
(Phosphopeptide 
binding) 
Effective on 
xenograft melanoma 
 (X. Zhang, et al., 2013) 
S3I-
201.1066 
(SF-1-1066) 
 
IC50=35µM 
(DNA binding) 
Kd=2.74 µM 
(Binding affinity) 
Effective on 
xenograft breast 
cancer 
 (Eiring, et al., 2015; X. 
Zhang, et al., 2010) 
BP-5-087 
 
IC50=5.6 µM 
(Phosphopeptide 
binding) 
  (Eiring, et al., 2015)  
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BP-1-102 
 
Kd=504 nM 
(Binding affinity)  
IC50=4.1 µM 
(STAT3 binding to 
RTK) 
IC50=6.8 µM 
(DNA binding) 
IC50=2-19 µM 
(Cytotoxicity)  
Effective on 
xenograft breast, 
colon, and lung 
cancers 
 (De Simone, et al., 2015; 
X. Zhang, et al., 2012) 
SH-5-07 
 
IC50=195-1120 nM 
(Cytotoxicity) 
  
(Haftchenary, et al., 
2013)  
SH-4-54 
 
Kd=300 nM 
(Binding affinity) 
 IC50=66 nM-9.2 µM  
(Cytotoxicity) 
Effective on 
xenograft 
glioblastoma 
 (Haftchenary, et al., 
2013) 
PG-S3-001 
 
Kd=324 nM 
(Binding affinity) 
IC50=3.7 µM 
(Cytotoxicity) 
Effective on patient-
derived pancreatic 
cancer xenograft 
 (Arpin, et al., 2016) 
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STX-0119 
 
IC50=5-10 µM 
(Cytotoxicity) 
Effective on 
xenograft lymphoma 
and glioblastoma 
 (Akiyama, et al., 2017; 
Ashizawa, et al., 2014; 
Ashizawa, et al., 2013; 
Ashizawa, et al., 2011; 
Matsuno, et al., 2010; 
Miyata, et al., 2017) 
BMA097 
 
IC50=0.9-3.9 µM 
(Cytotoxicity) 
Effective on 
xenograft breast 
cancer 
 (X. Li, et al., 2018) 
FLLL32 
 
IC50=0.53-0.77 µM 
(Cytotoxicity) 
Effective on xenograft 
osteosarcoma 
 (Bill, et al., 2010; 
Lin, Hutzen, Zuo, et 
al., 2010; Lin, et al., 
2016; Onimoe, et al., 
2012; Wei, et al., 
2011) 
FLLL31 
 
    
 (Lin, Hutzen, Zuo, 
et al., 2010) 
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Table 3. SH2 domain inhibitors in clinical trials 
Drug Structure Diseases Tested IC50 Ref 
STA-21 
 
Psoriasis 
IC50=12-20 µM 
(Cytotoxicity)  
(Ahmad, et al., 2017; C. 
L. Chen, et al., 2007; Cui, 
et al., 2014; Miyoshi, et 
al., 2011; Nadeem, et al., 
2017; Park, et al., 2014; 
Song, et al., 2005)  
OPB-31121 Not reported 
Leukemia, advanced cancer, solid 
tumor, Non-Hodgkin's lymphoma, 
multiple myeloma, and 
hepatocellular carcinoma 
IC50=0.3-100 nM  
(Cytotoxicity) 
 (Bendell, et al., 2014; 
Brambilla, et al., 2015; 
Hayakawa, et al., 2013; 
M. J. Kim, et al., 2013; 
Oh, et al., 2015; Okusaka, 
et al., 2015) 
OPB-51602 Not reported 
Nasopharyngeal carcinoma, 
advanced cancer, multiple 
myeloma, non-Hodgkin 
lymphoma, acute myeloid 
leukemia, acute lymphoid 
leukemia, chronic myeloid 
leukemia, solid tumor 
  
 (Ogura, et al., 2015; 
Wong, et al., 2015) 
Pyrimethamine 
 
Chronic lymphocytic leukemia, 
small lymphocytic leukemia 
  
 (J. Li, et al., 2017; 
Takakura, et al., 2011) 
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C188-9 
 
Breast cancer, HNSCC, non-small 
cell lung cancer, hepatocellular 
cancer, colorectal cancer, gastric 
adenocarcinoma, melanoma, 
advanced cancer 
IC50=0.4-18 µM 
(Cytotoxicity) 
 (Bharadwaj, et al., 2016; 
Jung, et al., 2017; Lewis, 
et al., 2015; Redell, et al., 
2011) 
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Table 4. Inhibitors targeting the DBD of STAT3 
Drug Structure IC50 Remarks References 
CPA-1 
 
IC50=5 µM 
(DNA binding) 
  (Turkson, Zhang, et 
al., 2004) 
CPA-7 
 
IC50=1.5 µM 
(DNA binding) 
Effective on xenograft glioma, 
melanoma, prostate and colon 
cancers but  not effective on 
xenograft tumors implanted in 
brain 
(Assi, et al., 2014; 
Liang, et al., 2016; 
Turkson, Zhang, et 
al., 2004; L. Zhang, 
et al., 2009)  
IS3-295 
 
IC50=1.4 µM 
(DNA binding) 
 (Turkson, et al., 
2005)  
Galiellalactone 
 
IC50=250-500 nM 
(SEAP expression) 
IC50=5 µM 
(Luciferase 
expression) 
 IC50=3 µM 
(Cytotoxicity) 
 
 (Canesin, et al., 
2016; Don-Doncow, 
et al., 2014; Escobar, 
et al., 2016; Garcia, 
et al., 2016; 
Hellsten, et al., 
2008; Hellsten, et 
al., 2011; Weidler, et 
al., 2000) 
GPA512 
 
IC50=4.81 µM 
(Cytotoxicity) 
Effective on xenograft prostate 
cancer 
 (Escobar, et al., 
2016) 
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InS3-54 
 
IC50=13.8 µM 
(Luciferase 
expression) 
IC50=20 µM 
(DNA binding) 
IC50=3.2-5.4 µM 
(Cytotoxicity) 
  
(Huang, et al., 2016; 
Huang, et al., 2014)  
InS3-54A18 
 
IC50=8.8-12.6 µM 
(Luciferase 
expression) 
IC50=3.2-4.7 µM 
(Cytotoxicity) 
Effective on xenograft lung 
cancer 
 (Huang, et al., 
2016) 
Pyrimidinetrione 
 
 
IC50=2.5-3.8 µM 
(DNA binding) 
 (Shan Sun, 2017) 
HO-3867 
 
 
  
Effective on xenograft ovarian 
cancer. 
(Y. Hu, et al., 2017; 
Rath, et al., 2014; 
Saini, et al., 2017; 
Selvendiran, Ahmed, 
Dayton, 
Kuppusamy, et al., 
2010; Tierney, et al., 
2012; Tierney, et al., 
2014) 
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Figure Legend 
Figure 1. JAK/STAT3 pathway. (A) STAT3 becomes activated by binding of a ligand to its 
receptor on the cell surface. Ligand binding leads to activation of JAK, which recruits and 
phosphorylates STAT3. STAT3 then forms a dimer moves into the nucleus and controls 
transcription. (B) Schematic domain structure of STAT3. pY and pS indicate the phosphorylated 
tyrosine 705 and serine 727 residues. NTD, amino terminal domain; CCD, coiled coil domain; 
DBD, DNA-binding domain; TAD, transactivation domain. (C) Crystal structure of STAT3 with 
representative STAT3 inhibitors BMA097 and inS3-54 docked into the SH2 and DBD, 
respectively. STAT3 structure (pdb code: 1bg1) containing residues 130 to 722 was colored by 
their domain consistent to the color scheme of the domain structure (B) in ribbon representation. 
BMA097 and inS3-54 are shown by their molecular surface in green and magenta, respectively. 
InS3-54 binds to the DBD and replaces the double strand DNA shown in gray. BMA097 binds to 
the SH2 domain and replaces the phosphorylated Tyr705 shown by as ball-and-stick in pink.   
Figure 2.  STAT3 decoy oligonucleotides and the modified cyclic structure. 
Figure 3. DBD inhibitor, inS3-54, and its derivatives. (A-B) The pharmacophore (A) and 
chemical structures (B) of inS3-54 and its active analogues targeting the DBD of STAT3. (C) 
Association of IC50 of active inS3-54 analogues with expression level of activated STAT3 in 
different cell lines. 
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